Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2007

View Archived Issues

Novel agents for treating diabetes and related disorders disclosed in recent patent literature

New agents with potential in the treatment of cancer disclosed in recent patent literature

New agents for musculoskeletal and connective tissue disorders disclosed in recent patents

Deterioration accelerated in amyotrophic lateral sclerosis patients given minocycline

MenACWY meningitis vaccine well tolerated, immunogenic in infants

Solvay reports third quarter 2007 results

Bristol-Myers Squibb advances growth hormone secretagogue to clinical development

Naryx Pharma completes enrollment in phase IIb clinical trial of Sybryx for chronic sinusitis

Xenome enters into joint research collaboration with Amylin for novel peptide therapeutics

Isis and Excaliard enter collaboration to develop antisense drugs for fibrotic diseases

Valeant completes enrollment of RESTORE2 phase III trial of retigabine for epilepsy

Xoma presents an update on the company's clinical development plans

Cyclacel presents an update on clinical development programs

Sustained improvement in SLE patients seen with belimumab over 2.5 years

Inhibition of soluble epoxide hydrolase protects against ischemic injury in vivo

AMT enters agreement with Digna and CIMA for program for late-stage liver cirrhosis

Pipex Pharmaceuticals enters CRADA to evaluate Coprexa for Huntington's disease

Israeli Government awards grant to Modigene for hGH-CTP development program

Fovea and Genzyme Corporation enter research collaboration in ophthalmology

CSL Behring reaches primary endpoint in IMPACT phase III clinical study of C1-INH

Osiris reports positive one-year interim results from phase I/II trial of Chondrogen

FDA accepts for filing UCB's NDA for Vimpat as adjunctive therapy in epilepsy

FDA accepts for filing UCB's NDA for Vimpat for diabetic neuropathic pain

FDA advisory committee to review Entereg NDA

Eisai submits Japanese NDA application for KES-524 for obesity management

E.U. approves Merck Serono's Cyanokit for cyanide poisoning

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...